The global metastatic uveal melanoma therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Uveal melanoma is a rare intraocular tumor in adults which originates in either iris, ciliary body, or choroid. Around 50% of the people develop metastatic disease after uveal melanoma diagnosis. It metastasizes to the liver and carries poor prognosis. The market growth is attributed to the increasing prevalence of uveal melanoma cancer all over the globe. Since the drugs used for metastatic uveal melanoma providing ample growth opportunities, the market players are constantly focusing on developing advanced solutions to treat the disease. Various types of therapeutics used to treat metastatic uveal melanoma include sunitinib malate, vincristine sulphate liposomal, ly-2801653, and sotrastaurin acetate among others.

The increasing geriatric population across the globe is also likely to propel the market growth during the forecast period. Elderly population is more prone to develop eye related medical issues. In fact, the prevalence of intraocular tumor in elderly population is comparatively higher owing to the wide prevalence of cataract among them. As per the National Center for Biotechnology Information (NCBI), uveal melanoma is a rare cancer, however, the most frequent include noncutaneous melanoma and primary malignancy of the eye in adults. Globally, it is estimated that there are 7,095 new cases of uveal melanoma annually with a mean age-adjusted incidence of 4.3 per million. All these factors lead to the growing demand for therapeutics solutions such as metastatic uveal melanoma therapeutics.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  AstraZeneca plc, Eli Lilly and Co., and Novartis International AG, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Metastatic Uveal Melanoma Therapeutics Market Report by Segment

By Type

• Sunitinib Malate

• Vincristine Sulfate Liposomal

• LY-2801653

• Sotrastaurin Acetate

• Others

By Application

• Hospital

• Clinic

• Others

Global Metastatic Uveal Melanoma Therapeutics Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa